

the **ADBL** report

Issue #132, May 2023

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Fiona Clement, PhD, (Chair)
Micheal Guirguis, BScPharm, PhD (Vice-Chair)
Daniel Altman, BSc, MD, FRCPC
Caitlin A. Clarke, BScPhm, PharmD
Margaret Gray, BSP, FCSHP
Michael Kolber, BSc, MD, CCFP, MSc
Naeem Ladhani, BScPharm
Nicholas Myers, BSc, MB, BS, MRCGP (UK)
Tony Nickonchuk, BScPharm

ALBERTA HEALTH LIAISON:

Andrea Nagle, BScPharm, LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)
Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Connie Lussier, BSP, MA

In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
 - ❖ *Products Originally Reviewed by CADTH*
 - ❖ *Biosimilar Drug Products Added*
- *Special Authorization Criteria Changes*

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on March 23, 2023. The Committee reviewed Manufacturer submissions for twenty-four (24) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of seventeen (17) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, forty-seven (47) Drug Products and Devices underwent Expedited Review for listing on the ADBL effective May 1, 2023.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.php>

Highlights of Products Originally Reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)

The following Drug Products were reviewed by CADTH and the Expert Committee and added to the ADBL effective May 1, 2023:

- **DOJOLVI* oral liquid** (triheptanoin) (UGX) via Special Authorization (SA)
- **INCRELEX* 40 mg/4 mL vial injection** (mecasermin) (ISP) via SA

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Products were added to the ADBL effective May 1, 2023:

- **ELONOX 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL & 100 mg/mL injection syringes and ELONOX HP 120 mg/0.8 mL & 150 mg/mL injection syringes** (enoxaparin sodium) (FKC)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective May 1, 2023:

- **FEBUXOSTAT* 80 mg tablets** (various brands: JPC, MAR & TEV)

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).